Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Twice Daily BR9003A vs Once Daily BR9003 in Healthy Adults
NCT04846998Phase 1Completed
- Sponsor
- Boryung
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of varenicline in nicotine dependence (6 arms), sponsored by Boryung. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration and Maximum Plasma Concentration. Started Mar 2021; status: completed.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT04846998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04846998.